CHCWM – Cancer & Hematology Centers of West Michigan

REGN3767-ONC-1613 (Regeneron)

Phase I, Open-Label, Dose-Escalation and Cohort Expansion First-In-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (Lag 3 inhibitor) Administered Alone or in Combination with REGN2810 (PD-1 inhibitor) in Patients with Advanced Malignancies.